Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Ruben Niesvizky, P.G. Richardson, P. Sonneveld, M.W. Schuster, M. Coleman, D. Irwin, E.A. Stadtmauer, T. Facon, J. Harousseau, A. Boral, K.C. Anderson

Blood (2006) 108 (11): 3529.

https://doi.org/10.1182/blood.V108.11.3529.3529

Published: 2006

Journal Articles

Hematologic Profiles in the Phase 3 APEX Trial.

Sagar Lonial, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3474.

https://doi.org/10.1182/blood.V106.11.3474.3474

Published: 2005

Journal Articles

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 2547.

https://doi.org/10.1182/blood.V106.11.2547.2547

Published: 2005

Journal Articles

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

J.F. San Miguel, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 366.

https://doi.org/10.1182/blood.V106.11.366.366

Published: 2005

Journal Articles

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Blood (2004) 104 (11): 1479.

https://doi.org/10.1182/blood.V104.11.1479.1479

Published: 2004

NARROW

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Hematologic Profiles in the Phase 3 APEX Trial.

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Email alerts

ASH Publications

American Society of Hematology

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Hematologic Profiles in the Phase 3 APEX Trial.

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only